The evidence-based risk prediction model using CRP and KL-6 combined with anti-MDA5 might also be useful for predicting prognosis in patients with DM-ILD; it is called the MCK (MDA5, CRP, and KL-6) model, identifying patients at low (<15%), moderate (15–49%), or high risk (≥50%) of mortality based on the number of risk factors. This evidence concerns the gene IFIH1 and interstitial lung disease.